Goldman Sachs Reiterates Buy Rating on Global Blood Therapeutics (GBT) on 'Key' European Approval
Tweet Send to a Friend
Goldman Sachs analyst Paul Choi reiterated a Buy rating and $69.00 price target on Global Blood Therapeutics (NASDAQ: GBT) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
